Veru (STU:FMW0) ROE % Adjusted to Book Value: -18.49% (As of Mar. 2026)

Veru STU:FMW0 34 ROE % Adjusted to Book Value is -18.49% as of Mar. 2026. GuruFocus rates STU:FMW0 with a GF Score™ of 34/100. The stock has 2 warning signs investors should review.

Veru's ROE % for the quarter that ended in Mar. 2026 was -30.70%. Veru's PB Ratio for the quarter that ended in Mar. 2026 was 1.66. Veru's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was -18.49%.

Veru ROE % Adjusted to Book Value Related Terms

Veru ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Veru's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Veru ROE % Adjusted to Book Value Chart

Veru Annual Data

Trend

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Sep24

Sep25

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

17.63

-71.13

-503.06

-409.26

-29.75

Veru Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-38.88	-28.69	11.78	-49.03	-18.49

STU:FMW0 vs AURX, PDSB, LTRN: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Veru's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Veru ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Veru's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Veru's ROE % Adjusted to Book Value falls into.

Save Embed

34GF Score

Veru Inc STU:FMW0

ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Veru ROE % Adjusted to Book Value Calculation

Veru's ROE % Adjusted to Book Value for the fiscal year that ended in Sep. 2025 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-86.56%	/	2.91
	=	-29.75%

Veru's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-30.70%	/	1.66
	=	-18.49%

Frequently Asked Questions Learn more about ROE % Adjusted to Book Value →

What does a ROE % Adjusted to Book Value of -18.49% mean?

Veru (STU:FMW0) has a ROE % Adjusted to Book Value of -18.49% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Veru and its competitors.

Is Veru's ROE % Adjusted to Book Value too high?

Veru's current ROE % Adjusted to Book Value is -18.49%. Overall, Veru has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.

How does Veru's ROE % Adjusted to Book Value compare to AURX and PDSB?

Veru's ROE % Adjusted to Book Value of -18.49% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROE % Adjusted to Book Value for a Biotechnology company?

A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROE % Adjusted to Book Value mean?

A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Veru and its competitors. Veru's current ROE % Adjusted to Book Value is -18.49%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Veru stock overvalued right now?

Veru (STU:FMW0) has a current ROE % Adjusted to Book Value of -18.49%. The current ROE % Adjusted to Book Value is -18.49%. Veru's overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROE % Adjusted to Book Value calculated?

ROE % Adjusted to Book Value is calculated from a company's financial statements. For Veru (STU:FMW0), the current ROE % Adjusted to Book Value is -18.49% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Veru Business Description

Industry Healthcare Biotechnology

Comparable Companies AURX PDSB LTRN KALA MGX HYPD TIL APLM IBO ACTU VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges VERU:USA

Address 2916 North Miami Avenue, Suite 1000, Miami, FL, USA, 33127

Website https://www.verupharma.com

Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.

34GF Score

Get the complete analysis for STU:FMW0

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.11

Price

View STU:FMW0 Analysis

See ROE % Adjusted to Book Value data for all stocks →